Key takeaways
Aimovig (erenumab) and Ajovy (fremanezumab) are both used to prevent migraines in adults, but they have some differences. Aimovig is a calcitonin gene-related peptide (CGRP) receptor antagonist, while Ajovy is a CGRP receptor blocker. Both work to block the proteins involved with migraine pain. Aimovig is injected once a month, whereas Ajovy offers two dosing options: once a month or once every three months. Both medications are available only as brand-name options and come in prefilled syringes or autoinjectors. Aimovig can cause constipation and high blood pressure, while Ajovy's main side effect is injection-site reactions. Additionally, Aimovig has a specific warning for those with latex allergies, which isn't mentioned for Ajovy. Neither medication is approved for use in children under 18 years old.
